Pfizer Presents First Data from Planned Interim Analysis of Pivotal Phase II MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) Mechanism of Action: Binds BCMA on myeloma cells and CD3 T cells, thereby bringing together T cells and activating them in the vicinity of the myeloma cell resulting in cell…

Phase I/II study of tusamitamab ravtansine (Sanofi) in patients with non-sq having locally advanced or metastatic NSCLC for which no standard alternative therapy is available. Tusamitamab ravtansine (SAR408701) is an ADC composed of a humanized monoclonal antibody that binds carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) and a cytotoxic maytansinoid that…

In the Phase Ib/II clinical trial of Sabizabulin in men with metastatic castration-resistant prostate cancer, Veru published important findings. Sabizabulin Mechanism of Action: Tubulin inhibitors; Tubulin polymerization inhibitors The alpha and beta-tubulin subunits of cellular intermediate filaments and microtubules are targeted, bound, and crosslinked by the first-in-class small chemical sabizabulin…

Every Patient in a Drug Trial Has Their Rectal Cancer Disappear In mismatch repair-deficient locally advanced rectal cancer, single-agent PD-1 blocking as a curative-intent treatment A total of 30 patients with clinical stage II and III dMMR rectal cancer will be enrolled in the single-arm Phase II study of dostarlimab…

ASCO 2022 Conference: Phase III IT-MATTERS study Highlights CEL-SCI’s leukocyte interleukin injection is an immunity booster for patients with Head and Neck squamous cell carcinoma! Multikine is CEL-SCI’s lead investigational immunotherapy product being developed as a potential first-line neoadjuvant therapy in patients with advanced primary squamous cell carcinoma of the…

In a Phase III trial, Gilead Sciences’ Trodelvy met the primary endpoints, lowering the probability of disease progression or death by 30%. In TROPiCS-02, Trodelvy was compared to chemotherapy in third-line HER2+, ER+ breast cancer. …

Pluvicto (177Lu-PSMA-617) was the first FDA-approved targeted radioligand therapy (RLT) for eligible patients with mCRPC in March 2022. Pluvicto (177Lu-PSMA-617) is a combination of a targeting chemical (ligand) and a therapeutic radioisotope. The FDA granted approval based on the results of the pivotal Phase III VISION trial, which showed a…

The efficacy and safety data for epcoritamab will be presented by Genmab and Abbvie. What is the market position of the antibody in Florida? EPCORE NHL-2 is a Phase Ib/II study in R/R FL that looks at the safety and preliminary efficacy of epcoritamab in combination with other drugs. Epcoritamab…

Diffuse Large B Cell Lymphoma is a deadly blood cancer that is the most frequent kind of non-Hodgkin lymphoma (NHL), with over 40,000 new cases diagnosed in Europe each year and another 25,000 in the United States. While the ASCO 2022 annual meeting is approaching, pharma behemoths such as Seagen…